Japan is considering increasing the stockpile of Fujifilm Holding Corp’s Avigan anti-flu drug during this fiscal year so that it can be used to treat 2 million people, according to a planning document seen by Reuters.
Local media yesterday reported that Japan was hoping to triple the production of the drug from current levels, which is enough to treat 700,000 people if used by COVID-19 patients.
Avigan, also known as favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014. Avigan is being tested in China as a treatment for COVID-19.
In the emergency stimulus package expected to be rolled out tomorrow, the government also plans to prioritize the clinical trial process of the drug so that it can be formally approved to be used in treating coronavirus patients.
According to the document, Japan also plans to boost subsidies to domestic companies that supply masks and disinfectants, and would secure enough capacity to supply 700 million masks a month.
The Nikkei newspaper reported that in efforts to reduce its dependence on China as its manufacturing hub, it would subsidize companies that would move some of their production facilities back to Japan.
Japanese Prime Minister Shinzo Abe on Friday said that a stimulus package to combat the pandemic would target small firms and households hardest hit by social distancing policies that are affecting consumption.
The package would include cash payouts to small firms and households facing sharp falls in income, Abe said.
The government would also urge private financial institutions to join government-affiliated lenders in offering zero-interest rate loans to cash-strapped small and medium-sized firms, he said.
Separately, Gilead Sciences Inc said it is donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.
The drug would be offered for compassionate use, expanded access and clinical trials, and would treat patients with severe symptoms, chairman and chief executive officer Daniel O’Day said in an open letter.
The company is also boosting its supply of remdesivir to more than 500,000 treatment courses by October and to more than 1 million by the end of the year.
Production time has also been accelerated to six months from one year, he said.
“While we are working with the utmost sense of urgency on the immediate needs before us, we are also looking forward,” he said. “Over the next weeks and months, we will be able to further increase our supplies of remdesivir as raw materials with long lead times become available for manufacture.”
The drugmaker last week said that it was switching to “expanded access” from a “compassionate use” program under which remdesivir was given.
Additional reporting by Bloomberg
PATENTS: MediaTek Inc said it would not comment on ongoing legal cases, but does not expect the legal action by Huawei to affect its business operations Smartphone integrated chips designer MediaTek Inc (聯發科) on Friday said that a lawsuit filed by Chinese smartphone brand Huawei Technologies Co (華為) over alleged patent infringements would have little impact on its operations. In an announcement posted on the Taiwan Stock Exchange, MediaTek said that it would not comment on an ongoing legal case. However, the company said that Huawei’s legal action would have little impact on its operations. MediaTek’s statement came after China-based PRIP Research said on Thursday that Huawei filed a lawsuit with a Chinese district court claiming that MediaTek infringed on its patents. The infringement mentioned in the lawsuit likely involved
EXPECTATIONS: The firm, which is on track to outpace global foundry industry revenue growth, said it expects constrained advanced process capacity amid stronger AI demand Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday increased its projected revenue growth for this year to above 25 percent, as stronger-than-expected demand for premium smartphones and artificial intelligence (AI) devices are to drive greater utilization of cutting-edge 3-nanometer and 5-nanometer chips. In April TSMC estimated 21 to 24 percent annual growth. The firm’s revenue growth is on track to greatly outpace the global foundry industry, which is expected to rise about 10 percent this year. “Over the past three months, we have observed stronger AI and high-end smartphone demand from our customers, which is to boost the overall capacity utilization for our leading-edge
INVESTMENT: The company’s planned complex in Texas would be the first 12-inch silicon wafer fab built in the US in more than 20 years, a GlobalWafers official said GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said it secured up to US$400 million in direct funding from the US Department of Commerce under the CHIPS and Science Act for the construction of two new advanced fabs in the US. Its subsidiaries GlobalWafers America and MEMC LLC are to build a 12-inch silicon wafer fab in Sherman, Texas, and another one in Missouri to produce silicon-on-insulator (SOI) wafers used to make leading-edge chips. “With the support of the [US President Joe] Biden Administration, we are honored to be bringing to American shores the world’s most cutting-edge 12-inch semiconductor
Nikon Corp is fielding strong demand for its legacy chipmaking machines in China, which is mobilizing resources to build its own semiconductor supply chain. Inquiries for the Japanese precision maker’s lithography tools have surged in China, Nikon president Muneaki Tokunari said. The company is set to revamp a lithography machine geared for decades-old manufacturing processes. Its NSR-2205iL1, launching this summer, would serve the market for mature chip technology and Nikon expects to sell more than 10 units of the machine annually, said Tokunari, who is also chief operating officer and chief financial officer. New companies are sprouting up in China to make